Core Viewpoint - Dianthus Therapeutics (NASDAQ:DNTH) is a biopharmaceutical company focused on treatments for autoimmune and inflammatory diseases, with a recent price target set at $145 indicating a potential upside of 79.28% from its current price of $80.88 [1][5] Company Performance - The stock has experienced a remarkable 13-fold increase over the past two years, driven by advancements in its experimental treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), significantly boosting investor interest [2][5] - Currently, DNTH is priced at $80.68, reflecting a 23.74% increase, or a rise of $15.48, with fluctuations between $78 and $84.86 today, indicating strong investor activity [3][5] - The company has a market capitalization of approximately $2.92 billion and a trading volume of about 2.9 million shares, with the lowest price over the past year being $13.37, showcasing significant growth [4]